Lancet (London, England)Jun 30, 2026

How mRNA vaccines work and their safety and effectiveness for public health

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 1, 2026

Abstract

Billions of doses of mRNA vaccines have been administered globally during the COVID-19 pandemic.

mRNA vaccines are characterized by rapid development timelines, scalable manufacturing, and strong immune responses with a favorable safety profile.
These vaccines operate by transiently expressing proteins in cells without integrating into the genome and are rapidly cleared from the body.
Safety assessments are supported by data from randomized trials, ongoing monitoring, and pharmacovigilance systems.
Real-world effectiveness has been demonstrated across various demographics, including different age groups, pregnant individuals, and immunocompromised populations.
Public perception and confidence in vaccines are critical for successful deployment and acceptance.
The evidence supports mRNA vaccines as a flexible platform for future infectious disease prevention, as well as potential applications in cancer and autoimmune treatment.

Simplified

mRNA vaccines represent a transformative advance in vaccinology, combining rapid development timelines, scalable manufacturing, and strong immunogenicity with a favourable safety profile. Global deployment of mRNA vaccines during the COVID-19 pandemic provided an unprecedented real-world evaluation of this platform, with billions of doses administered across diverse populations. In this Review, we critically examine the safety and efficacy of mRNA vaccines from mechanistic, preclinical, clinical, and public health perspectives. We outline the biological basis of mRNA vaccines, including their transient cytoplasmic expression, lack of genomic integration, and rapid clearance, distinguishing them clearly from other gene therapies. We synthesise evidence on vaccine components, manufacturing quality controls, and regulatory standards that underpin safety, alongside data from randomised trials, post-authorisation surveillance, and active pharmacovigilance systems. We also review real-world effectiveness across age groups, pregnancy, and populations that are immunocompromised, along with the effects on transmission. Last, we address public perception and vaccine confidence, and discuss implications for next-generation mRNA vaccines, including strategies to reduce reactogenicity, improve breadth and durability of immunity, enhance global access, and support sustainable public trust. Together, the accumulated evidence affirms mRNA vaccines as a safe, effective, and adaptable platform with enduring relevance for future infectious disease prevention and public health preparedness, and for the treatment of cancer and autoimmunity.